| 10/25/2024 | CV | Market Commentary: TeraWulf convertibles shoot higher; MicroStrategy strengthens; DexCom notes active
|
| 10/22/2024 | CV | Market Commentary: iRhythm convertible notes shoot higher; DexCom active; MicroStrategy notes trade mixed
|
| 10/22/2024 | CV | Market Commentary: Morning Commentary: MicroStrategy convertible notes mixed in early secondary trading
|
| 7/26/2024 | CV | Market Commentary: DexCom convertible notes lower as stock plummets; Liberty moves to upside; trading slows
|
| 7/26/2024 | CV | Market Commentary: Morning Commentary: DexCom convertible notes drop as stock plummets; Liberty improves
|
| 10/26/2023 | CV | Market Commentary: Convertibles trading ‘anemic’; Enovis active; DexCom lower; Anywhere Real Estate up
|
| 10/17/2023 | CV | Market Commentary: High-grade convertible notes in demand; DexCom rebounds; Rivian hits new outright high
|
| 10/13/2023 | CV | Market Commentary: DexCom, Insulet convertible notes active, level off after sell-off; PagerDuty below par
|
| 10/13/2023 | CV | Market Commentary: Morning Commentary: DexCom, Insulet convertible notes active, level off after sell-off
|
| 8/30/2023 | CV | Market Commentary: Insulet convertible notes in focus; DexCom gains; Wayfair active in secondary market
|
| 8/25/2023 | CV | Market Commentary: Affirm convertibles gain on earnings; DexCom notes hit new low; Fluor up outright
|
| 8/25/2023 | CV | Market Commentary: Morning Commentary: Secondary quiet as markets digest Fed speech; DexCom trades lower
|
| 5/5/2023 | CV | DexCom greenshoe increases 0.375% convertibles to $1.25 billion
|
| 5/3/2023 | CV | Market Commentary: Zynex on tap; DexCom convertibles in focus, jump on debut; CMS, FirstEnergy gain
|
| 5/3/2023 | CV | Market Commentary: Morning Commentary: DexCom convertibles in focus, jump on debut; CMS, FirstEnergy gain
|
| 5/3/2023 | CV | New Issue: DexCom prices upsized $1.1 billion five-year convertibles to yield 0.375%, up 37.5%
|
| 5/2/2023 | CV | Market Commentary: DexCom upsizes convertibles offering; CMS, FirstEnergy strong on debut; Chegg craters
|
| 5/2/2023 | CV | Market Commentary: Morning Commentary: DexCom convertibles on deck; CMS, FirstEnergy strong on debut
|
| 5/2/2023 | CV | DexCom talks $1 billion five-year convertibles to yield 0.25%-0.5%, up 37.5%-42.5%
|
| 10/7/2022 | CV | Market Commentary: Semtech’s new convertibles fall along with broader semiconductor market; tech names off
|
| 10/7/2022 | CV | Market Commentary: Morning Commentary: Semtech upsizes convertibles; DexCom higher; Twitter still in play
|
| 7/29/2022 | CV | Market Commentary: Enphase convertible notes improve; DexCom declines; Akamai active; Avaya in trouble
|
| 7/29/2022 | CV | Market Commentary: Morning Commentary: Enphase convertible notes continue to gain; DexCom declines
|
| 6/18/2021 | CV | Market Commentary: Algonquin Power units flat outright, contract dollar-neutral; large seller in market
|
| 12/23/2020 | CV | Market Commentary: DISH convertibles rebound; Palo Alto, Pioneer Natural Resources gain in active trading
|
| 12/23/2020 | CV | Market Commentary: Morning Commentary: Convertibles secondary market quiet; DexCom notes active early
|
| 10/28/2020 | CV | Market Commentary: Arch Resources convertibles on tap; Akamai, DexCom down after earnings beat expectations
|
| 5/12/2020 | CV | Market Commentary: Convertibles primary set to price $2.05 billion in five deals; new notes flood secondary
|
| 5/12/2020 | CV | New Issue: DexCom prices upsized $1.05 billion 5.5-year convertibles to yield 0.25%, up 42.5%
|
| 5/11/2020 | CV | Market Commentary: Convertibles primary to price $3.8 billion of notes in five deals; pricing ‘aggressive’
|
| 5/11/2020 | CVLM | DexCom to buy back up to $260 million 0.75% convertibles due 2022
|
| 5/11/2020 | CV | Market Commentary: Morning Commentary: Convertibles primary to price $3.6 billion of notes over five deals
|
| 5/11/2020 | CV | DexCom talks $850 million convertibles due November 2025 to yield 0.125%-0.625%, up 40%-45%
|
| 2/14/2020 | CV | Market Commentary: SSR Mining convertible notes in focus on call news; Wayfair active; Dexcom, Insulet gain
|
| 8/19/2019 | CV | Market Commentary: Convertibles see pockets of improvement on swap; volumes light; recent issuance eyed
|
| 6/10/2019 | CV | Market Commentary: Calendar balloons; Dominion Energy, Vonage, Zynga on tap; Coupa Software gains continue
|
| 4/11/2019 | CV | Market Commentary: PAR Technology convertible notes expand; Intercept down outright, up on hedge; biotechs active
|
| 3/19/2019 | CV | Market Commentary: Euronet Worldwide convertibles in focus; DexCom notes active; Dermira gains continue
|
| 3/19/2019 | CV | Market Commentary: Morning Commentary: Euronet Worldwide convertibles in focus; DexCom notes active
|
| 1/7/2019 | CV | Market Commentary: Convertibles secondary tone improves; Ares Capital dominates trading; biotechs strong
|
| 12/3/2018 | CV | Market Commentary: Tesaro convertibles active, up on buyout by GlaxoSmithKline; iQIYI, Liberty Media gain
|
| 12/3/2018 | CV | DexCom greenshoe exercised, lifts 0.75% convertibles to $850 million
|
| 11/29/2018 | CV | Market Commentary: iQIYI offering upsized, looks cheap; DexCom, Liberty Media expand; Ensco notes active
|
| 11/28/2018 | CV | Market Commentary: iQIYI notes on tap; DexCom, Electronics for Imaging, Liberty Media sell $1.24 billion
|
| 11/28/2018 | CV | Market Commentary: Morning Commentary: DexCom, Electronics for Imaging, Liberty Media sell $1.24 billion
|
| 11/28/2018 | CV | New Issue: DexCom sells $750 million five-year convertible notes to yield 0.75%, up 32.5%
|
| 11/27/2018 | CV | Market Commentary: Convertibles market eyes DexCom, Electronics for Imaging, Liberty Media offerings
|
| 11/27/2018 | CV | Market Commentary: Morning Commentary: Market eyes DexCom, Electronics for Imaging, Liberty Media offerings
|
| 11/26/2018 | CV | Market Commentary: Convertibles calendar balloons; DexCom, Liberty Media, Electronics for Imaging on tap
|
| 11/26/2018 | CV | DexCom talks $750 million five-year convertible notes to yield 0.25%-0.75%, up 32.5%-37.5%
|
| 5/3/2018 | CV | Market Commentary: Convertibles market weighs Five9, Teladoc offerings with mixed views; NXP, Dexcom active
|
| 9/28/2017 | CV | Market Commentary: Western Asset prices cheap; DexCom steals the show as convertibles drop; PTC in focus
|
| 9/28/2017 | CV | Market Commentary: Morning Commentary: Western Asset prices cheap; DexCom steals the show as convertibles drop
|
| 6/12/2017 | CV | DexCom greenshoe lifts five-year 0.75% convertibles to $400 million
|
| 5/12/2017 | CV | Market Commentary: Stanley Black & Decker notches strong debut; Dermira deal touted; Becton Dickinson does well
|
| 5/11/2017 | CV | Market Commentary: Primary sees deal flow of $3.15 billion; Becton prices; Dermira rises; Black & Decker on tap
|
| 5/9/2017 | CV | Market Commentary: New deals from DexCom, Kaman active post-pricing; Dermira adds to calendar; Becton on tap
|
| 5/9/2017 | CV | Market Commentary: Morning Commentary: New issues from DexCom, Kaman climb above par in active trading
|
| 5/8/2017 | CV | New Issue: DexCom sells upsized $350 million five-year 0.75% convertibles, up 35%
|
| 5/8/2017 | CV | Market Commentary: DexCom, Kaman, Becton Dickinson enter market; Horizon falters as guidance lowered; Cobalt up
|
| 5/8/2017 | CV | Market Commentary: Morning Commentary: DexCom, Kaman, Becton Dickinson plan to tap market; Horizon falters
|
| 5/8/2017 | CV | DexCom selling $300 million five-year convertible notes to yield 0.75%-1.25%, up 30%-35%
|
| 6/11/2010 | CVLM | DexCom opts to redeem $1.5 million of 4.75% convertible notes due 2027
|
| 3/15/2010 | CV | DexCom plans to swap shares for $18 million in 4.75% convertible notes
|
| 3/11/2010 | CV | DexCom to issue common shares for $11.15 million 4.75% convertibles
|
| 2/24/2010 | CV | DexCom issues shares in exchange for $9.75 million 4.75% convertibles
|
| 2/1/2010 | CV | DexCom issues shares in exchange for $9.1 million 4.75% convertibles
|
| 11/4/2009 | CVHY | DexCom files $100 million shelf covering preferreds, stock and debt
|
| 3/7/2007 | CV | DexCom greenshoe exercised, lifting convertibles to $60 million
|
| 3/6/2007 | CV | New Issue: DexCom prices $40 million 20-year convertibles at 4.75%, up 20%
|
| 3/6/2007 | CV | Market Commentary: Bausch & Lomb gains; DexCom quiet on debut; Barnes absent in gray; Cypress, Developers launch deals
|
